权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

SBHW-PREDICT (The role of PRoteomics, gEnetics, and Directed Imaging using CT)

SBHW-PREDICT（蛋白质组学、遗传学和 CT 定向成像的作用）

基本信息

批准号：
9264579
负责人：
Shaista Malik
金额：
$ 65.59万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2015
资助国家：
美国
起止时间：
2015-07-15 至 2020-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/9264579
关键词：
Address Biological Biological Markers Blood Tests Calcium Cardiac Cardiovascular system Cells Cessation of life Chemotaxis Clinical Coronary Coronary artery Coronary heart disease Data Discrimination Disease Early treatment Eotaxin Event Family Family history of Fibrosis Freezing Funding Genetic Genetic Markers Genetic Predisposition to Disease Genetic Risk Genetic screening method Heart Heart Diseases Homeostasis Image Imaging Device Incidence Individual Inflammation Interdisciplinary Study Interleukin-6 Medicare Medicare claim Myocardial Infarction Outcome Participant Pathway interactions Phenotype Plasma Plasma Cells Population Predictive Factor Predictive Value Predisposition Prevention Proteomics Recording of previous events Research Risk Risk Assessment Risk Factors Role Sampling Serum Signal Transduction Stable Disease Stress Survivors Testing Time Troponin United States National Institutes of Health Vascular calcification X-Ray Computed Tomography adiponectin alpha-Fetoproteins base circulating biomarkers cohort density disorder risk experience follow-up genetic profiling imaging approach imaging biomarker improved indexing lipoprotein-associated phospholipase A(2)mortality non-invasive imaging novel marker premature prevent pro-brain natriuretic peptide (1-76)prognostic value public health relevance screening

项目摘要

DESCRIPTION (provided by applicant): In our proposed study, SBHW-PREDICT (The role of PRoteomics, gEnetics, and Directed Imaging using CT), we will assess whether identification of at-risk individuals, using imaging markers, a biomarker profile or a combination of the two, improves reclassification and discrimination over traditional risk factors, particularly in those wth either a family history of coronary heart disease (CHD) or higher genetic predisposition for CHD. We have used data from 1312 participants of the first NIH-funded study of predictive value of CAC, the South Bay Heart Watch (SBHW) study, to calculate plaque density. In preliminary analyses, we have found that higher plaque density is related to lower incidence of CVD events in this cohort. In the proposed study, we will use serum and cell samples collected at baseline, 20 years ago, from the SBHW and retrospectively assess outcomes using administrative data from Medicare and the National Death Index to address the following aims and objectives: 1) Using Medicare Claims and National Death Index data assess prognostic value of baseline CAC, as well as coronary calcium density for long-term (20 year) CHD event rate; 2) Using serum and cell samples collected at baseline, assess whether a multi-biomarker approach using circulating markers from different biological pathways would have additional reclassification value over traditional risk factors; 3) Determine whether compared to family history a CHD genetic risk score is more predictive of events; and 4) Determine whether a genetic score modifies the prognostic value of an imaging marker (CAC) or a multiple biomarker score or a combination of the two in those at higher predisposition (based on either family history or genetic score) for CHD versus those at low genetic risk. The experience of our multidisciplinary research team, unique 20 year follow-up period after baseline CAC, linkage to Medicare claims data and Death Index data, genetic and biomarker profiles using frozen serum and cell samples, and follow-up of the original cohort survivors are major strengths of this proposal. Results of thi project will assess the utility of a complementary genetic marker, multi-biomarker, and imaging approach to risk assessment.